Objective To explore the effect of Docetaxel combined with Carboplatin in the treatment of ovarian cancer and its influence on immune status and blood flow parameters.Methods A total of 68 patients with advanced ovarian cancer treated in Yangjiang People′s Hospital from January 2018 to January 2020 were selected as the research objects and divided into the observation group (35 cases) and the control group (33 cases) according to the treatment plan, the observation group was treated with Docetaxel combined with Carboplatin, the control group was treated with Paclitaxel combined with Cisplatin.The efficacy, immune indexes, blood flow parameters, median survival time and adverse reactions of the two groups were compared.Results There was no statistically significant difference in the efficacy between the two groups (P>0.05).After treatment, CD3+, CD4+ in the observation group were higher than those in the control group, and the differences were statistically significant (P<0.05).After treatment, the maximum systolic flow velocity(PSV) of the observation group was lower than that of the control group, while the vascular resistance index (RI) and pulse index (PI) of the observation group were higher than those of the control group, and the differences were statistically significant (P<0.05).There were no statistically significant differences in the median survival time and the incidence of adverse reactions between the two groups (P>0.05).Conclusion Docetaxel combined with Carboplatin has a good effect in the treatment of advanced ovarian cancer, which can significantly improve the immune status and ovarian hemodynamic parameters.
罗蕙雨 张翠娟 林金凤. 多西他赛联合卡铂治疗对卵巢癌患者机体免疫状态及血流参数的影响[J]. 中国当代医药, 2021, 28(11): 17-20转25.
LUO Hui-yu ZHANG Cui-juan LIN Jin-feng. Effect of Docetaxel combined with Carboplatin on immune status and blood flow parameters in patients with ovarian cancer. 中国当代医药, 2021, 28(11): 17-20转25.
Ghoneum A,Afify H,Salih Z,et al.Role of tumor microenvironment in ovarian cancer pathobiology[J].Oncotarget,2018,9(32):22 832-22 849.
[5]
Manchanda R,Menon U.Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer[J].Int J Gynecol Cancer,2018,28(1):34-42.
[6]
Ukawa S,Tamakoshi A,Mori M,et al.Association between average daily television viewing time and the incidence of ovarian cancer:findings from the Japan Collaborative Cohort Study[J].Cancer Causes Control,2018,29(5):1-7.
[7]
Jones BA,Varambally S,Arend RC.Histone Methyltransferase EZH2:A Therapeutic Target for Ovarian Cancer[J].Mol Cancer Ther,2018,17(3):591-602.
Henderson JT,Webber EM,Sawaya GF.Screening for Ovarian Cancer:Updated Evidence Report and Systematic Review for the US Preventive Services Task Force[J].JAMA,2018,319(6):595-606.
[11]
Pasquier J,Gosset M,Geyl C,et al.CCL2/CCL5 secreted by the stroma induce IL-6/PYK2 dependent chemoresistance in ovarian cancer[J].Mol Cancer,2018,17(1):47.
[12]
Helm CW,Richard SD,Pan J,et al.Hyperthermic intraperitoneal chemotherapy in ovarian cancer first report of the HYPER-O registry[J].Int J Gynecol Cancer,2018,20(1):61-69.
[13]
Taki M,Abiko K,Baba T,et al.Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation[J].Nat Commun,2018,9(1):1685.
[17]
Grossman DC,Curry SJ,Owens DK,et al.Screening for Ovarian Cancer:US Preventive Services Task Force Recommendation Statement[J].JAMA,2018,319(6):588-594.